Puig sets 2032 Uriage target and €1bn dermocosmetics platform plan

Sophie Lindqvist

Puig plans to take full ownership of Isdin in Q1 2027, subject to regulatory approvals, adding a skincare brand with approximately €650m in 2025 revenue to a platform that would exceed €1bn in pro forma net revenue upon completion.

Jose Manuel Albesa presented the plan at Puig’s Capital Markets Day 2026 in Madrid, Spain, on 28 October 2026. The Spanish beauty group’s chief executive wants to transform Puig into a “global dermocosmetics champion,” giving the category a central role in the company’s next phase of growth.

What is driving Uriage’s 2032 sales target?

Puig wants to double Uriage’s sales by 2032. The French dermocosmetics brand will pursue that increase through three stated routes:

• Entry into higher-value dermocosmetics categories.
• A stronger presence in Europe and Latin America.
• Accelerated e-commerce and deeper partnerships with major pharmacy and para-pharmacy groups.

For product teams, the first route makes category expansion and assortment work central to the growth plan. For commercial and procurement teams, the second and third routes shift attention toward market sequencing, pharmacy relationships and digital fulfilment. The announcement did not specify product categories, formulations or a current sales baseline.

Marc Toulemonde, Puig’s President, Derma, said the objective is to move Uriage from “a regional champion into a global dermocosmetics leader.” For pharmacy buyers and category managers, that means building distribution and brand recognition beyond Uriage’s regional base, not relying on one channel.

Takeaway: Uriage’s 2032 target depends on higher-value categories, wider geography and faster pharmacy and digital routes to market.

What does the Isdin acquisition add?

Puig has agreed to acquire Isdin from Corporación Químico-Farmacéutica Esteve (CQFE), which currently owns the business. The agreement gives Puig full ownership, and the company will make Isdin a key pillar of its dermocosmetics platform when the transaction completes.

Isdin generated approximately €650m in revenue in 2025. Its addition to Uriage and Apivita, Puig’s Greek natural skin and hair care brand, would create a three-brand platform with more than €1bn in pro forma net revenue once the deal closes.

The distinction between pro forma and reported revenue matters for financial analysis. Until completion and regulatory approval, the platform remains a forward structure rather than a combined operating result; no acquisition price or integration timetable accompanied the announcement.

For compliance and finance teams, Q1 2027 is therefore a conditional checkpoint. For brand and supply-chain teams, the three-brand platform raises the importance of coordinating launches, inventory and channel commitments across Isdin, Uriage and Apivita as Puig expands them.

Takeaway: Isdin supplies the scale, but approval and integration determine when the €1bn platform becomes operating revenue.

How large is the dermocosmetics opportunity?

Fortune Business Insights valued the global dermocosmetics market at US$47.9bn in 2025 and projects it to reach US$117bn by 2034. The forecast implies a US$69.1bn market-size increase, or about 144% growth from the 2025 base.

This market backdrop supports Puig’s decision to place dermocosmetics at the centre of its growth strategy, although the analyst forecast does not guarantee company-level share gains. Puig’s wider goal is to exceed €8bn in annual net revenue by 2032 and become a top-four premium beauty company.

The group has not set out how much of the €8bn target will come from the dermocosmetics platform. The €1bn pro forma figure therefore provides scale for the three-brand structure, while Uriage’s doubling target supplies the clearest brand-level operating goal.

Takeaway: Puig is targeting scale in a market forecast to reach US$117bn, but the group’s 2032 revenue ambition remains broader than dermocosmetics.

How will the brands reach more consumers?

Puig plans to expand all its dermocosmetics brands into new markets and channels, including specialist beauty, department stores, travel retail and digital platforms. This extends the route-to-market agenda beyond Uriage’s named pharmacy and para-pharmacy push and gives Isdin and Apivita scope for broader distribution.

For beauty buyers and procurement teams, the order and pace of those channel openings will determine when wider distribution can translate into volume. Product and compliance leads will need to coordinate the three-brand portfolio across the announced market and channel mix, while the announcement included no detailed launch calendar.

Takeaway: The next hard checkpoint is regulatory approval and completion of the Isdin acquisition in Q1 2027; until then, watch Uriage’s channel rollout and evidence against its 2032 doubling target.